Insmed Incorporated (INSM)
Insmed Incorporated operates in the Biotechnology industry of the Healthcare sector, headquartered in Bridgewater, NJ, US. The stock last traded at $132.62, up 0.04% on the session, giving a market capitalisation of $28.75B. On trailing twelve-month figures it carries a trailing P/E of -32.27, a net margin of -76.9%. Its beta of 0.79 implies it has historically moved less than the broad market.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Insmed Incorporated is most often compared with the following Healthcare names: